BCL2 and Miyoshi myopathy: A single-center retrospective study assessing the OS from time of venetoclax refractoriness in MM with t(11;14) or high BCL2 profile showed that the median PFS from the initiation of venetoclax was significantly longer when venetoclax was used as earlier line of treatment (fewer than three prior lines) at 23.2 months vs. 10.4 months in those with three or more prior lines, supporting the use of venetoclax as earlier lines of therapy in t(11:14) MM patients (129).